enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage gene-based immunotherapy company, announced the grant of inducement equity awards to three newly-hired employees, effective July 31, 2025. The awards consist of non-qualified stock options to purchase a total of 93,200 common shares at an exercise price of $3.79 per share, matching the closing price on the grant date. These options have a 10-year term and will vest over four years, with 25% vesting after one year of employment and the remainder vesting monthly over the next three years, contingent on continued employment. The grants were approved by the Company's independent Compensation Committee in alignment with NASDAQ Listing Rule 5635(c)(4), and while issued outside the 2023 Incentive Equity Plan, they adhere to its terms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.